The Hereditary testing refers to genetic tests that help identify inherited mutations linked to diseases such as cancer, cardiovascular conditions, neurological disorders, and rare genetic syndromes. These tests are widely used for screening, diagnosis, and risk assessment, helping healthcare providers deliver personalized treatment plans. Growing adoption of precision medicine and increasing integration of artificial intelligence in genetic analysis are further fueling the growth of this market globally.
According to Fortune Business Insights, the global hereditary testing market size was valued at USD 18.8 billion in 2025 and is projected to grow from USD 21.55 billion in 2026 to USD 64.38 billion by 2034, exhibiting a CAGR of 14.66% during the forecast period. The market is witnessing rapid expansion due to the increasing prevalence of genetic disorders, rising awareness about early disease detection, and continuous advancements in genomic technologies. Hereditary testing has emerged as a critical component in modern healthcare, enabling individuals to identify genetic risks and adopt preventive healthcare strategies.
The hereditary testing market is primarily driven by the increasing incidence of genetic disorders and hereditary diseases worldwide. Rising awareness among individuals regarding genetic screening and preventive healthcare has significantly boosted demand for hereditary testing solutions. Additionally, advancements in next-generation sequencing (NGS) technologies and decreasing costs of genetic testing are making these services more accessible to a broader population.
Another key driver is the growing adoption of personalized medicine, where genetic insights are used to tailor treatments according to an individual’s genetic profile. Healthcare providers are increasingly utilizing hereditary testing to enhance clinical decision-making, improve patient outcomes, and reduce long-term healthcare costs.
However, the market faces certain restraints, including ethical concerns related to genetic data privacy and limited reimbursement policies in some regions. High initial costs of advanced testing technologies and lack of skilled professionals in genetic counseling may also hinder market growth to some extent.